ONYX Pharmaceuticals Inactive 10-K2000 FY Annual report

Filed: 2 Apr 01, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	7th grade Good

New words: accelerate, accessing, accuracy, AffiliationEdward, allocated, America, antibody, antitumor, attributable, avoid, batch, Belgium, Carboplatin, Click, collateral, cytokine, deal, Deed, Description, discontinue, easier, element, epinephrine, extra, FIN, gel, George, Germany, guided, guiding, ImClone, implied, impossible, inappropriate, inconclusive, input, Intradose, Leonard, listed, managerial, marketplace, Matrix, moderately, monoclonal, navigate, necessarily, needle, North, OSI, parent, post, prolonged, purifying, purpose, raf, regression, remeasurement, reputation, revise, routine, scalable, spend, spread, Taxol, terminology, trend, unavailable, undesirable, unwilling, XOMA

Removed: Accrued, addressed, Advisor, approach, begun, berendt, breached, Capitalized, cellular, challenged, circulating, circumvented, colella, commercialized, computer, computing, cytotoxic, damage, delivered, destroy, devote, director, discriminate, division, earlier, edward, eliminated, ending, endoscopic, engineer, engineering, ensure, environment, exploring, expose, extension, factory, fee, forgiven, Fourth, Francisco, frequently, funded, Furniture, gathered, Harvard, hepatic, inability, inactivated, infected, infection, intraperitoneal, intrinsic, invalidated, jurisdiction, largely, leased, length, Los, Machinery, maintenance, metastatic, michael, Michigan, noncurrent, Nuclear, objection, observed, opposed, ovarian, Ovary, pegylation, physically, predicted, predictive, President, RAC, recruit, rectum, rendered, retainer, samuel, San, School, slowly, software, sought, spectrum, suffered, suitable, systemic, transient, understood, vest, viable, warner, wider

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ONYX Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

QuickLinks -- Click here to rapidly navigate through this document

EXHIBIT 23.1

Consent of Ernst & Young LLP, Independent Auditors

We consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-49285, No. 333-46366, No. 333-37144 and No. 333-33322) and the Registration Statements on Forms S-8 (No. 333-60805, No. 333-48146, No. 333-84113, No. 333-04839 and No. 333-34681) pertaining to the 1996 Employee Stock Purchase Plan, the 1996 Non-Employee Directors' Stock Option Plan and the 1996 Equity Incentive Plan of Onyx Pharmaceuticals, Inc. of our report dated February 23, 2001, with respect to the financial statements of Onyx Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2000.

Palo Alto, California
March 28, 2001

QuickLinks

Consent of Ernst & Young LLP, Independent Auditors